JP4814501B2 - Antioxidant function improver - Google Patents
Antioxidant function improver Download PDFInfo
- Publication number
- JP4814501B2 JP4814501B2 JP2004255576A JP2004255576A JP4814501B2 JP 4814501 B2 JP4814501 B2 JP 4814501B2 JP 2004255576 A JP2004255576 A JP 2004255576A JP 2004255576 A JP2004255576 A JP 2004255576A JP 4814501 B2 JP4814501 B2 JP 4814501B2
- Authority
- JP
- Japan
- Prior art keywords
- antioxidant function
- hydrogen atom
- group
- salt
- antioxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003963 antioxidant agent Substances 0.000 title claims description 38
- 230000003078 antioxidant effect Effects 0.000 title claims description 37
- 230000000694 effects Effects 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims description 11
- 229960002749 aminolevulinic acid Drugs 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 10
- 239000011707 mineral Substances 0.000 claims description 10
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 9
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 9
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 230000037406 food intake Effects 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- 239000011669 selenium Substances 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000003623 enhancer Substances 0.000 claims 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 1
- 230000003064 anti-oxidating effect Effects 0.000 claims 1
- 239000011572 manganese Substances 0.000 claims 1
- 229910052748 manganese Inorganic materials 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 description 31
- -1 n-propanoyl group Chemical group 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 125000002252 acyl group Chemical group 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000019688 fish Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000001055 magnesium Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 125000006686 (C1-C24) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ZLHFONARZHCSET-UHFFFAOYSA-N 5-aminolevulinic acid hydrochloride Chemical compound Cl.NCC(=O)CCC(O)=O ZLHFONARZHCSET-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000277338 Oncorhynchus kisutch Species 0.000 description 1
- 241000277275 Oncorhynchus mykiss Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001282110 Pagrus major Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- PGZIKUPSQINGKT-UHFFFAOYSA-N dialuminum;dioxido(oxo)silane Chemical compound [Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O PGZIKUPSQINGKT-UHFFFAOYSA-N 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 239000005648 plant growth regulator Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、動脈硬化症、癌、糖尿病などの生活習慣病、しみ、そばかす等の異常な色素沈着、皮膚の炎症、皮膚の老化などの予防治療に有用な抗酸化機能向上剤に関する。 The present invention relates to an anti-oxidant function improving agent useful for preventive treatment of lifestyle diseases such as arteriosclerosis, cancer, diabetes, abnormal pigmentation such as stains and freckles, skin inflammation, and skin aging.
スーパーオキシドラジカルや過酸化水素に代表される活性酸素が、細胞障害性を有し、癌、リウマチ、シミ、シワ等の原因となっていることは広く知られている。また、コレステロールを運ぶLDLは活性酸素により酸化LDLに変化し、変化した酸化LDLは動脈硬化の原因になることが知られている。 It is widely known that active oxygen typified by superoxide radical and hydrogen peroxide has cytotoxicity and causes cancer, rheumatism, stains, wrinkles and the like. Further, it is known that LDL carrying cholesterol is changed to oxidized LDL by active oxygen, and the changed oxidized LDL causes arteriosclerosis.
そこで抗酸化作用を有する薬剤は、動脈硬化症、癌、糖尿病などの生活習慣病、しみ、そばかす等の異常な色素沈着、皮膚の炎症、皮膚の老化などの予防治療薬として有用であるといわれ、種々の抗酸化作用成分が見出されている。例えば、ビタミンEやビタミンC等の天然物や、BHT(3,5−tert−ブチル−4−ヒドロキシトルエン)やBHA(2,3−tert−ブチル−ヒドロキシアニソール)等の合成品、生薬等に抗酸化作用のあることが知られている(特許文献1)。
しかしビタミンEやビタミンCは天然物として安全ではあるものの、抗酸化剤としての効果は不十分であり、BHTやBHAには発ガン性の疑いがもたれている等の問題がある。また生薬由来のものについても、抗酸化剤としての効果は不十分であった。
従って、本発明の目的は、安全に長時間摂取できる抗酸化機能向上剤を提供することにある。
However, although vitamin E and vitamin C are safe as natural products, their effects as antioxidants are insufficient, and BHT and BHA have problems such as suspected carcinogenicity. Moreover, the effect as an antioxidant was insufficient for those derived from herbal medicines.
Accordingly, an object of the present invention is to provide an antioxidant function improver that can be safely ingested for a long time.
そこで本発明者は、種々のアミノ酸の薬理作用を検討してきたところ、5−アミノレブリン酸に代表される、安全性の高いδ−アミノ酸類が抗酸化酵素として知られているスーパーオキシドジスムターゼ(SOD)又はグルタチオンペルオキシダーゼ(GPx)活性を向上させ、優れた抗酸化機能向上作用を有することを見出し、本発明を完成するに至った。 Thus, the present inventors have studied the pharmacological action of various amino acids, and as a result, superoxide dismutase (SOD) in which highly safe δ-amino acids represented by 5-aminolevulinic acid are known as antioxidant enzymes. Or the glutathione peroxidase (GPx) activity was improved, it discovered that it had the outstanding antioxidant function improvement, and came to complete this invention.
すなわち、本発明は、δ−アミノ酸、その誘導体又はその塩を有効成分とする抗酸化機能向上剤を提供するものである。 That is, the present invention provides an antioxidant function improver comprising a δ-amino acid, a derivative thereof or a salt thereof as an active ingredient.
本発明によれば、抗酸化機能が低下した動物、例えば高齢化に伴ない、抗酸化機能が低下した人を含む動物の抗酸化機能を向上させることができ、動脈硬化症、癌、糖尿病などの生活習慣病、しみ、そばかす等の異常な色素沈着、皮膚の炎症、皮膚の老化などを予防又は改善することができる。 ADVANTAGE OF THE INVENTION According to this invention, the antioxidant function of the animal in which the antioxidant function declined, for example, the animal including the person in which the antioxidant function fell with aging, can be improved, arteriosclerosis, cancer, diabetes, etc. It is possible to prevent or ameliorate life-style related diseases, stains, freckles and other abnormal pigmentation, skin inflammation, and skin aging.
本発明の抗酸化機能向上剤の有効成分は、δ−アミノ酸、その誘導体又はその塩である。当該δ−アミノ酸類としては、次式(1) The active ingredient of the antioxidant function improver of the present invention is a δ-amino acid, a derivative thereof or a salt thereof. The δ-amino acids include the following formula (1)
(式中、R1は水素原子又はアシル基を示し、R2は水素原子又は置換基を有していてもよいアルキル基を示す)
で表される5−アミノレブリン酸類又はその塩が挙げられる。
当該5−アミノレブリン酸類は、光動力学的治療における光増感剤(特表2004−505105号)、植物成長調節剤(特開平07−53487号)、除草剤(特開平05−117110号)、魚類病原性微生物、寄生虫の感染治療(特開2001−316255号)、豚成育促進剤(特開2003−40770号)等として有用であることは知られているが、抗酸化機能に対する作用については全く知られていない。
(Wherein R 1 represents a hydrogen atom or an acyl group, and R 2 represents a hydrogen atom or an alkyl group which may have a substituent)
The 5-aminolevulinic acid represented by these or its salt is mentioned.
The 5-aminolevulinic acids are photosensitizers in photodynamic therapy (Japanese Patent Publication No. 2004-505105), plant growth regulators (JP 07-53487 A), herbicides (JP 05-117110 A), It is known that it is useful as a fish pathogenic microorganism, parasitic infection treatment (Japanese Patent Laid-Open No. 2001-316255), pig growth promoter (Japanese Patent Laid-Open No. 2003-40770), etc. Is not known at all.
式(1)中、R1で示されるアシル基としては、例えば炭素数1〜24のアルカノイル基、芳香族アシル基、ベンジルオキシカルボニル基等が挙げられる。好ましいアシル基の具体例としては、例えばアセチル基、n−プロパノイル基、n−ブタノイル基、n−ペンタノイル基、n−ヘキサノイル基、n−ノナノイル基、ベンジルオキシカルボニル基等が挙げられる。このうち、炭素数1〜6のアルカノイル基がより好ましい。 In formula (1), examples of the acyl group represented by R 1 include an alkanoyl group having 1 to 24 carbon atoms, an aromatic acyl group, and a benzyloxycarbonyl group. Specific examples of preferable acyl groups include acetyl group, n-propanoyl group, n-butanoyl group, n-pentanoyl group, n-hexanoyl group, n-nonanoyl group, benzyloxycarbonyl group and the like. Among these, a C1-C6 alkanoyl group is more preferable.
また、R2で示される置換を有していてもよいアルキル基としては、例えば置換基を有していてもよい直鎖若しくは分岐鎖の、又は環状構造を有する炭素数1〜24のアルキル基等が挙げられる。このアルキル基が有してもよい置換基としては、例えばヒドロキシ基、アルコキシ基、フェニル基等が挙げられる。このような置換基を有していてもよいアルキル基の好ましい例としては、例えばメチル基、エチル基、n−プロピル基、イソプロピル基、n−ペンチル基、n−ヘキシル基、シクロヘキシル基、n−ヘプチル基、n−オクチル基、n−ノニル基、n−ドデシル基、n−ヘキサデシル基、ベンジル基、フォネチル基、3−フェニルプロピル基、ヒドロキシエチル基、エトキシエチル基等を挙げることができる。このうち炭素数1〜6のアルキル基がより好ましい。なお、上記R1は、アミノ基の置換基、R2はカルボン酸基の置換基を示しているが、例示したこれらの置換基は、5−アミノレブリン酸のみならず、δ−アミノ酸の置換基でもある。 Moreover, as an alkyl group which may have a substitution shown by R < 2 >, for example, a C1-C24 alkyl group which has a linear or branched or cyclic structure which may have a substituent Etc. Examples of the substituent that this alkyl group may have include a hydroxy group, an alkoxy group, and a phenyl group. Preferable examples of the alkyl group which may have such a substituent include, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-pentyl group, n-hexyl group, cyclohexyl group, n- Examples include a heptyl group, an n-octyl group, an n-nonyl group, an n-dodecyl group, an n-hexadecyl group, a benzyl group, a phonethyl group, a 3-phenylpropyl group, a hydroxyethyl group, and an ethoxyethyl group. Among these, a C1-C6 alkyl group is more preferable. R 1 represents a substituent of an amino group, and R 2 represents a substituent of a carboxylic acid group. These exemplified substituents are not only 5-aminolevulinic acid but also a δ-amino acid substituent. But there is.
δ−アミノ酸又はその誘導体の塩としては、例えば塩酸塩、臭化水素酸塩、ヨウ化水素酸塩、リン酸塩、硝酸塩、硫酸塩、酢酸塩、プロピオン酸塩、トルエンスルホン酸塩、コハク酸塩、シュウ酸塩、乳酸塩、酒石酸塩、グリコール酸塩、メタンスルホン酸塩、酪酸塩、吉草酸塩、クエン酸塩、フマル酸塩、マレイン酸塩、リンゴ酸塩等の酸付加塩、及びナトリウム塩、カリウム塩、カルシウム塩等の金属塩、アンモニウム塩、アルキルアンモニウム塩等が挙げられる。なお、これらの塩は使用時において水溶液又は粉体として用いられる。 Examples of salts of δ-amino acids or derivatives thereof include hydrochloride, hydrobromide, hydroiodide, phosphate, nitrate, sulfate, acetate, propionate, toluenesulfonate, and succinic acid. Acid addition salts such as salt, oxalate, lactate, tartrate, glycolate, methanesulfonate, butyrate, valerate, citrate, fumarate, maleate, malate, and Examples thereof include metal salts such as sodium salt, potassium salt and calcium salt, ammonium salt, alkylammonium salt and the like. These salts are used as an aqueous solution or powder at the time of use.
以上のδ−アミノ酸、その誘導体又はそれらの塩は、水和物又は溶媒和物を形成していてもよく、またいずれかを単独で又は2種以上を適宜組み合わせて用いることができる。 The above δ-amino acids, derivatives thereof or salts thereof may form hydrates or solvates, and any of them may be used alone or in combination of two or more.
δ−アミノ酸、その誘導体又はそれらの塩(以下、「δ−アミノ酸類」と称する。)は、化学合成、微生物による生産、酵素による生産のいずれの方法によっても製造することができる。また、前記δ−アミノ酸又はその塩のうち、5−アミノレブリン酸は、特開昭48−92328号公報、特開昭62−111954号公報、特開平2−76841号公報、特開平6−172281号公報、特開平7−188133号公報、特開平11−42083号公報等に記載の方法に準じて製造することができる。上記のようにして製造されたδ−アミノ酸若しくはその塩又はそれらの誘導体、それらの精製前の化学反応溶液や発酵液は、有害な物質を含まない限り、分離精製することなくそのまま用いることができる。また市販品なども使用することができる。 δ-amino acids, derivatives thereof or salts thereof (hereinafter referred to as “δ-amino acids”) can be produced by any method of chemical synthesis, production by microorganisms, and production by enzymes. Among the δ-amino acids or salts thereof, 5-aminolevulinic acid is disclosed in JP-A-48-92328, JP-A-62-111954, JP-A-2-76841, and JP-A-6-172281. It can be produced according to the method described in JP-A-7-188133 and JP-A-11-42083. The δ-amino acid or a salt thereof or a derivative thereof produced as described above, a chemical reaction solution or a fermentation solution before purification thereof can be used as they are without separation and purification as long as they do not contain harmful substances. . Moreover, a commercial item etc. can also be used.
上記δ−アミノ酸類は、後記実施例に示すように、老齢化して抗酸化機能が低下したマウスのSOD活性又はGPx活性を増強させ、低下した抗酸化機能を向上させる作用をする。従って、上記δ−アミノ酸類は人を含む動物の抗酸化機能向上剤として有用であり、特に加齢により抗酸化機能が低下した人を含む動物の抗酸化機能向上剤として有用である。 As will be described later in Examples, the δ-amino acids enhance the SOD activity or GPx activity of mice that are aged and have a decreased antioxidant function, and improve the decreased antioxidant function. Therefore, the above-mentioned δ-amino acids are useful as an antioxidant function improver for animals including humans, and are particularly useful as an antioxidant function improver for animals including persons whose antioxidant functions have decreased due to aging.
また、本発明の抗酸化機能向上剤は、ミネラルを含有させるか、同時に摂取することにより、さらにその効果を向上させることができる。ミネラルとしては、鉄、亜鉛、銅、リン、カルシウム、マグネシウム、カリウム、セレン、クロム、マンガン、ヨウ素、ホウ素、ケイ素、バナジウム、モリブデン、コバルトなどが挙げられるが、特に好ましくは銅、亜鉛、マンガン、セレンである。これらのミネラル分は単独で、又は二種以上を組み合わせて用いることができる。ミネラルの化学的性状としては生物に害を与えるものでなければどんなものを用いてもよい。 Moreover, the antioxidant function improvement agent of this invention can improve the effect further by containing a mineral or ingesting simultaneously. Examples of the mineral include iron, zinc, copper, phosphorus, calcium, magnesium, potassium, selenium, chromium, manganese, iodine, boron, silicon, vanadium, molybdenum, cobalt, and the like, particularly preferably copper, zinc, manganese, Selenium. These mineral components can be used alone or in combination of two or more. Any chemical properties of minerals may be used as long as they do not harm the organism.
本発明の抗酸化機能向上剤には、他の抗酸化剤及び必要に応じて栄養剤等を加えることができる。他の抗酸化剤としては、ユビキノン、フェルラ酸などのポリフェノール類、N−アセチルシステイン、システイン、カテコール、トコフェロール、カテキン、ケルセチンなどのフラボノイド類等が挙げられる。栄養剤としては、例えば、必須アミノ酸類、非必須アミノ酸類、ビタミン類、ハーブ、プロテイン、種々の酵素などが挙げられる。 The antioxidant function improver of the present invention can contain other antioxidants and, if necessary, nutrients. Examples of other antioxidants include polyphenols such as ubiquinone and ferulic acid, and flavonoids such as N-acetylcysteine, cysteine, catechol, tocopherol, catechin, and quercetin. Examples of nutrients include essential amino acids, non-essential amino acids, vitamins, herbs, proteins, various enzymes, and the like.
本発明の抗酸化機能向上剤は、δ−アミノ酸類の粉末、δ−アミノ酸類を水に溶かした水溶液、上記方法で製造したδ−アミノ酸類を含む発酵液を、賦形剤等の担体に吸着させて使用することもできる。担体の種類としては、一般的なものでよく、結晶性セルロース、ゼラチン、でんぷん、デキストリン、油かす、パン酵母、ビール酵母、酒酵母、ワイン酵母、脱脂粉乳、乳糖、動物性及び植物性油脂、無水リン酸カルシウム、炭酸カルシウム、ステアリン酸マグネシウム、ケイ酸アルミン酸マグネシウム、メタケイ酸アルミン酸マグネシウムなどが挙げられる。 The antioxidant function improver of the present invention comprises a powder of δ-amino acids, an aqueous solution in which δ-amino acids are dissolved in water, and a fermentation liquid containing δ-amino acids produced by the above method as a carrier such as an excipient. It can also be used after being adsorbed. As a kind of carrier, it may be a general one, crystalline cellulose, gelatin, starch, dextrin, oil cake, baker's yeast, brewer's yeast, liquor yeast, wine yeast, skim milk powder, lactose, animal and vegetable oils and fats, Anhydrous calcium phosphate, calcium carbonate, magnesium stearate, magnesium aluminate silicate, magnesium metasilicate aluminate and the like can be mentioned.
本発明の抗酸化機能向上剤の剤型としては、注射剤、錠剤、カプセル剤、細粒剤、シロップ剤、坐薬等が挙げられる。これらは溶剤、分散媒、増量剤、賦形剤等を適宜用い、常法に従って製造することができる。また、食品の形態として摂取してもよい。 Examples of the dosage form of the antioxidant function improver of the present invention include injections, tablets, capsules, fine granules, syrups, and suppositories. These can be produced according to a conventional method using a solvent, a dispersion medium, an extender, an excipient and the like as appropriate. Moreover, you may ingest as a form of food.
本発明の抗酸化機能向上剤を水溶液として調製する場合には、δ−アミノ酸類が5−アミノレブリン酸の場合、有効成分である5−アミノレブリン酸、その誘導体又はそれらの塩の分解を防ぐため、水溶液がアルカリ性とならないように留意する必要がある。アルカリ性となってしまう場合は、酸素を除去することによって有効成分の分解を防ぐことができる。 When the antioxidant function improver of the present invention is prepared as an aqueous solution, when δ-amino acids are 5-aminolevulinic acid, in order to prevent decomposition of 5-aminolevulinic acid, its derivative or a salt thereof as an active ingredient, Care must be taken so that the aqueous solution does not become alkaline. When it becomes alkaline, decomposition of the active ingredient can be prevented by removing oxygen.
本発明の抗酸化機能向上剤は、本剤を摂取してその抗酸化機能を向上させることができればよく、本剤の使用方法に制限はないが、好ましい態様について以下に示す。 The antioxidant function-improving agent of the present invention is not limited as long as the agent can be ingested to improve its antioxidant function, and the method of using the agent is not limited, but preferred embodiments are shown below.
本剤を用いた抗酸化機能向上剤の対象となる動物は特に限定されないが、哺乳類、爬虫類、鳥類、両性類、魚類などの脊椎動物が好ましい。これらの例としては、人、牛、豚、羊、やぎ、マウス、ラット、ウサギ、犬、猫、鶏、鶉、ニジマス、コイ、ウナギ、イワナなどの淡水魚、ギンザケ、ブリ、マダイ、サバ、マグロなどの海水魚などが挙げられる。 The target animals for the antioxidant function improver using this agent are not particularly limited, but vertebrates such as mammals, reptiles, birds, amphibians and fish are preferred. Examples of these include freshwater fish such as humans, cows, pigs, sheep, goats, mice, rats, rabbits, dogs, cats, chickens, salmon, rainbow trout, carp, eel, char, coho salmon, yellowtail, red sea bream, mackerel, tuna And saltwater fish.
本剤の抗酸化機能向上剤の使用は動物の成育のどの時点でも可能であるが、好ましくは抗酸化機能、例えばSOD活性やGPx活性が低下した以降が好ましい。抗酸化機能向上剤の使用は、人であれば15歳以降が好ましく、35歳以降が特に好ましい。 The use of the antioxidant function improver of the present agent is possible at any time during the growth of the animal, but preferably after the antioxidant function, for example, SOD activity or GPx activity is lowered. The use of the antioxidant function improver is preferably 15 years old or later, and particularly preferably 35 years old or later, for humans.
本発明の抗酸化機能向上剤の摂取方法としては特に限定されないが、経口摂取、注射による摂取又は経腸による摂取が挙げられ、なかでも経口摂取が好ましい。 The method for ingesting the antioxidant function-improving agent of the present invention is not particularly limited, and examples thereof include oral ingestion, ingestion or intestinal ingestion, and oral ingestion is particularly preferable.
本剤は、1度の摂取でも十分な効果を示すが、さらに効果を強めるために複数回摂取することもできる。摂取する剤あたりの効果は複数回摂取の方が効果的であり、毎日少量ずつ摂取するのが効率的な使用方法である。 This drug shows a sufficient effect even if it is taken once, but it can be taken multiple times to further enhance the effect. The effect per ingested agent is more effective when taken multiple times, and it is an efficient usage method to take a small amount every day.
本剤の対象動物1kgあたり1回の摂取量は、0.001mg〜1000mgが好ましく、さらには0.001mg〜100mg、特に0.001mg〜50mgが好ましい。本剤の摂取量は、成育が旺盛な時期ほど、また摂取回数の少ないほど多くの量が必要である。適切な範囲を超えた摂取は不経済であるばかりか日光傷害を起こす可能性があるため望ましくない。 The amount of intake of this drug per 1 kg of the target animal is preferably 0.001 mg to 1000 mg, more preferably 0.001 mg to 100 mg, and particularly preferably 0.001 mg to 50 mg. The intake of this drug should be increased as the period of growth increases and as the number of intakes decreases. Ingestion beyond the appropriate range is not desirable because it is not economical and can cause sun injury.
またミネラル類を併用する場合は同時に使用してもよいし別々に使用してもよい。使用するミネラルの種類、その使用方法及びその使用量は通常市販されているミネラル類と同じで差し支えない。その使用量は、例えば銅の場合には成人男性で1日あたり0.5〜10mgであればよく、1〜5mgが好ましい。亜鉛の場合には1〜40mgであればよく、5〜20mgが好ましい。マンガンの場合には0.5〜11mgであればよく、2〜8mgが好ましい。セレンの場合には10〜250μgであればよく、20〜100μgが好ましい。 Moreover, when using together minerals, you may use simultaneously and may use separately. The kind of mineral to be used, the method of using the same, and the amount of the mineral used may be the same as those of commercially available minerals. For example, in the case of copper, the amount used may be 0.5 to 10 mg per day for an adult male, with 1 to 5 mg being preferred. In the case of zinc, it may be 1 to 40 mg, and 5 to 20 mg is preferable. In the case of manganese, it may be 0.5 to 11 mg, preferably 2 to 8 mg. In the case of selenium, it may be 10 to 250 μg, and preferably 20 to 100 μg.
次に実施例を挙げて本発明をさらに詳細に説明するが、本発明はこれに何ら限定されない。 EXAMPLES Next, although an Example is given and this invention is demonstrated further in detail, this invention is not limited to this at all.
実施例1
一週間予備飼育したマウス(70週齢、BALB/cAJcl)にマウス体重1kg当たり5−アミノレブリン酸(ALA)塩酸塩10mgを一日一回、7日間連続して摂取させた。ALA塩酸塩は蒸留水で0.5mg/mL濃度に調整し、マウスに経口投与した。試験後マウスを解剖し、マウスの胸腺を採取し組織のスーパーオキシドジスムターゼ(SOD)活性を測定した。採取した胸腺に0.25Mショ糖水溶液1.0mLを加え、ホモジナイズ後、10,000Gで10分間遠心後の上澄み液を酵素液として用いた。測定は抗酸化能測定用発光試薬MPEC(2−メチル−6−p−メトキシフェニルエチニルイミダゾピラジノン;mw=279.1)法(アトー株式会社製)によった。すなわち、0.1Mリン酸カリウム緩衝液pH7.5、125μL、酵素液10μL、0.1units/mLキサンチンオキシダーゼ60μL、蒸留水45μL、0.3mM MPEC10μL、反応終量250μLとし、Luminescencer−PSN(アトー株式会社製)に分注し、0.72mMヒポキサンチンpH7.5を50μL加え、発光させた。発光阻害率の算出は酵素液の代わりに緩衝液を用いた。計算は標準SODを用いて検量線を作成して、これから濃度計算を行った。
また併せてグルタチオンペルオキシダーゼ(GPx)活性を測定した。分光光度計のセル内に37℃に保持した0.6mL反応混合液(0.05M−K−phosphate buffer, pH7.0、1mM NaN3、1mM EDTA、4mM GSHを含む)と2mM H2O2 0.1mL、酵素液50μLを加え、総量1mL、直接分光光度計にて波長340nm(ODat340nm)で2分間スキャンさせた(20mm/min)。空試料は酵素液の代わりに蒸留水を
用いた。
計算はチャート上から直線の傾きΔOD(ΔOD=Δcm(y軸の変化量)×ODMax
/fullcm)を求めNADPHの分子吸光係数a=6.3cm2/μmoleを用いて
Example 1
Mice preliminarily raised for one week (70 weeks old, BALB / cAJcl) were ingested with 10 mg of 5-aminolevulinic acid (ALA) hydrochloride per kg of mouse body weight once a day for 7 consecutive days. ALA hydrochloride was adjusted to a concentration of 0.5 mg / mL with distilled water and orally administered to mice. After the test, the mouse was dissected, the mouse thymus was collected, and the tissue superoxide dismutase (SOD) activity was measured. To the collected thymus, 1.0 mL of a 0.25M sucrose aqueous solution was added, and after homogenization, the supernatant obtained after centrifugation at 10,000 G for 10 minutes was used as an enzyme solution. The measurement was performed by the luminescence reagent MPEC (2-methyl-6-p-methoxyphenylethynylimidazopyrazinone; mw = 279.1) method (manufactured by Ato Co., Ltd.) for measuring antioxidant capacity. Specifically, 0.1 M potassium phosphate buffer pH 7.5, 125 μL, enzyme solution 10 μL, 0.1 units / mL xanthine oxidase 60 μL, distilled water 45 μL, 0.3 mM MPEC 10 μL, reaction final amount 250 μL, Luminescencer-PSN (Ato shares) And 50 μL of 0.72 mM hypoxanthine pH 7.5 was added to cause light emission. For the calculation of the luminescence inhibition rate, a buffer solution was used instead of the enzyme solution. For the calculation, a standard curve was prepared using a standard SOD, and the concentration was calculated from this.
In addition, glutathione peroxidase (GPx) activity was also measured. A 0.6 mL reaction mixture (containing 0.05 M K-phosphate buffer, pH 7.0, 1 mM NaN 3 , 1 mM EDTA, 4 mM GSH) and 2 mM H 2 O 2 kept at 37 ° C. in the spectrophotometer cell. 0.1 mL and 50 μL of enzyme solution were added, and a total amount of 1 mL was directly scanned with a spectrophotometer at a wavelength of 340 nm (ODat 340 nm) for 2 minutes (20 mm / min). The empty sample used distilled water instead of the enzyme solution.
The calculation is performed by calculating the slope of the straight line ΔOD (ΔOD = Δcm (y-axis change)) × ODMax
/ Fullcm) using the NADPH molecular extinction coefficient a = 6.3 cm 2 / μmole.
(数1)
GPx活性=V/adv×ΔOD/Δt
(Vは反応溶液量、d=light path=1cm、v=酵素量、Δt=時間の変化量min)
(Equation 1)
GPx activity = V / adv × ΔOD / Δt
(V is the amount of reaction solution, d = light path = 1 cm, v = enzyme amount, Δt = time change min)
によって求めた。
試験は1区あたり雄と雌のマウス各5匹、計10匹で実施、値は平均値を示した。ALAを処理した区においては、雄、雌いずれの場合もSOD活性又はGPx活性が向上していることを確認した。
Sought by.
The test was carried out with 5 male mice and 5 female mice per group, for a total of 10 mice, and the values showed average values. In the group treated with ALA, it was confirmed that SOD activity or GPx activity was improved in both male and female cases.
Claims (8)
で表される化合物又はその塩を有効成分とする抗酸化機能向上剤。 The following formula (1)
The antioxidant function improvement agent which uses the compound or its salt represented by these as an active ingredient.
で表される化合物又はその塩を、1日に体重1kgあたり0.001〜1000mg摂取するものである請求項1〜5のいずれか1項記載の抗酸化機能向上剤。 The following formula (1)
In a compound or a salt thereof, an anti-oxidation function improving agent according to any one of claims 1 to 5 is also of you intake 0.001~1000mg per body weight 1kg per day.
で表される化合物又はその塩を有効成分とするスーパーオキシドジスムターゼ活性増強剤。The superoxide dismutase activity enhancer which uses the compound or its salt represented by these as an active ingredient.
で表される化合物又はその塩を有効成分とするグルタチオンペルオキシダーゼ活性増強剤。The glutathione peroxidase activity enhancer which uses the compound or its salt represented by these as an active ingredient.
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004255576A JP4814501B2 (en) | 2004-09-02 | 2004-09-02 | Antioxidant function improver |
EP14153023.8A EP2727589B1 (en) | 2004-09-02 | 2005-08-26 | Constitutional function-improving agents |
PCT/JP2005/015560 WO2006025286A1 (en) | 2004-09-02 | 2005-08-26 | Constitutional function-improving agents |
AU2005278649A AU2005278649B8 (en) | 2004-09-02 | 2005-08-26 | Constitutional function-improving agents |
CN2005800295100A CN101010076B (en) | 2004-09-02 | 2005-08-26 | Immune function-improving agent |
KR1020077007605A KR100966318B1 (en) | 2004-09-02 | 2005-08-26 | Constitutional function-improving agents |
CA2752569A CA2752569C (en) | 2004-09-02 | 2005-08-26 | .delta.-amino acid as an exercise function-improving agent |
CA2579032A CA2579032C (en) | 2004-09-02 | 2005-08-26 | Use of an .delta.-amino acid as thymocyte growth agent |
CN201010150020A CN101822661A (en) | 2004-09-02 | 2005-08-26 | Immune function-improving agent |
EP05774552.3A EP1785132B1 (en) | 2004-09-02 | 2005-08-26 | Constitutional function-improving agents |
US11/661,688 US8790712B2 (en) | 2004-09-02 | 2005-08-26 | Constitutional function-improving agents |
ES05774552.3T ES2459366T3 (en) | 2004-09-02 | 2005-08-26 | Agents improving the constitutive function |
KR1020097023324A KR20100016341A (en) | 2004-09-02 | 2005-08-26 | Constitutional function-improving agents |
NO20071165A NO336392B1 (en) | 2004-09-02 | 2007-03-01 | Means to improve immunological function |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004255576A JP4814501B2 (en) | 2004-09-02 | 2004-09-02 | Antioxidant function improver |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006069963A JP2006069963A (en) | 2006-03-16 |
JP4814501B2 true JP4814501B2 (en) | 2011-11-16 |
Family
ID=36150948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004255576A Expired - Lifetime JP4814501B2 (en) | 2004-09-02 | 2004-09-02 | Antioxidant function improver |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4814501B2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9095165B2 (en) * | 2008-10-27 | 2015-08-04 | Sbi Pharmaceuticals Co., Ltd. | Prophylactic/ameliorating agent for adult diseases comprising 5-aminolevulinic acid, derivative of 5-aminolevulinic acid, or salt of 5-aminolevulinic acid or the derivative of 5-aminolevulinic acid as active ingredient |
JP5611548B2 (en) * | 2009-07-08 | 2014-10-22 | Sbiファーマ株式会社 | Cancer preventive / ameliorating agent containing 5-aminolevulinic acid or a derivative thereof, or a salt thereof as an active ingredient |
JP5818906B2 (en) * | 2011-10-12 | 2015-11-18 | Sbiファーマ株式会社 | Preventive and / or therapeutic agent for side effects of anticancer agents |
US9475755B2 (en) | 2011-10-12 | 2016-10-25 | SBI Pharmaceuticals Co., Ltd | Prophylactic agent for chronic kidney disease |
US9469598B2 (en) | 2011-10-12 | 2016-10-18 | Sbi Pharmaceuticals Co., Ltd. | Erythropoietin production-promoting agent |
CN103930103B (en) | 2011-10-12 | 2016-08-24 | 思佰益药业股份有限公司 | The one-tenth activity promoter of transplant organ |
PL2873417T3 (en) | 2012-07-13 | 2019-09-30 | Sbi Pharmaceuticals Co., Ltd. | Immune tolerance inducer |
US20170056351A1 (en) * | 2014-02-25 | 2017-03-02 | University Of Occupational And Environmental Health, Japan | Composition for inducing tumor immunity |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0969790A2 (en) * | 1997-02-21 | 2000-01-12 | Beiersdorf Aktiengesellschaft | Compositions for treating acne rosacea |
-
2004
- 2004-09-02 JP JP2004255576A patent/JP4814501B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2006069963A (en) | 2006-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8790712B2 (en) | Constitutional function-improving agents | |
CA2455539C (en) | Pig growth enhancer and pig growth enhancing method | |
EP2415468B1 (en) | D-glutamic acid for alleviating ultraviolet radiation-induced damage | |
EP2478899B1 (en) | Composition for alleviating ultraviolet irradiation-induced damage | |
EA025256B1 (en) | Composition useful for the treatment of lipid metabolism disorders | |
JP4814501B2 (en) | Antioxidant function improver | |
JPWO2006033355A1 (en) | Oral preparation for preventing or improving dry skin | |
JP2005082495A (en) | Cerebral cell-protecting composition | |
JP4814568B2 (en) | Immune function improver | |
JP4814567B2 (en) | Health function improver | |
JP2021078397A (en) | Lipid decrease promoter | |
WO2022224776A1 (en) | Lipid decrease promoter | |
JP4930977B2 (en) | Eggshell quality improver | |
WO2015002279A1 (en) | Composition for promoting glutathione production | |
US20090148426A1 (en) | Composition for life extension and method of extending the life | |
US20240247028A1 (en) | Peptide compositions for slowing degradation of vitamin mineral supplements, foods, pharmaceutical and cosmetics | |
FR2461462A1 (en) | NEW FEED COMPOSITION FOR ANIMALS | |
MX2010001863A (en) | Usage of phytoceutic compositions with nutritional, antimicrobial and antioxidant properties during the growth-fattening period of chicken. | |
MX2009013644A (en) | Usage of phytoceutic compositions with nutritional properties during the growth-fattening period of salmonidae fish. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070117 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080827 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080827 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101019 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101215 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110823 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110826 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4814501 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140902 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140902 Year of fee payment: 3 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140902 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |